Tools   Select Another Resource Report Type

http://www.ncbi.nlm.nih.gov/books/NBK5330/

THIS RESOURCE IS NO LONGER IN SERVICE, documented May 10, 2017. A pilot effort that has developed a centralized, web-based biospecimen locator that presents biospecimens collected and stored at participating Arizona hospitals and biospecimen banks, which are available for acquisition and use by researchers. Researchers may use this site to browse, search and request biospecimens to use in qualified studies. The development of the ABL was guided by the Arizona Biospecimen Consortium (ABC), a consortium of hospitals and medical centers in the Phoenix area, and is now being piloted by this Consortium under the direction of ABRC. You may browse by type (cells, fluid, molecular, tissue) or disease. Common data elements decided by the ABC Standards Committee, based on data elements on the National Cancer Institute''s (NCI''s) Common Biorepository Model (CBM), are displayed. These describe the minimum set of data elements that the NCI determined were most important for a researcher to see about a biospecimen. The ABL currently does not display information on whether or not clinical data is available to accompany the biospecimens. However, a requester has the ability to solicit clinical data in the request. Once a request is approved, the biospecimen provider will contact the requester to discuss the request (and the requester''s questions) before finalizing the invoice and shipment. The ABL is available to the public to browse. In order to request biospecimens from the ABL, the researcher will be required to submit the requested required information. Upon submission of the information, shipment of the requested biospecimen(s) will be dependent on the scientific and institutional review approval. Account required. Registration is open to everyone.Searchable book regarding molecular imaging and contrast agents (under development, in clinical trials or commercially available for medical applications) that have in vivo data (animal or human) published in peer-reviewed scientific journals prior to June 30 of 2013. 1444 agents are currently listed and there will be no more updates. Also available is a downloadable list of FDA approved contrast agents (Latest update: January 2013) and a Molecular Imaging Probes and Contrast Agents List (MIP & CA List) created by the MICAD staff by screening the PubMed / MedLine databases and other appropriate sources of such information. Only agents used in animal or human studies yielding in vivo data were selected for inclusion in the list. The list is by no means considered complete. No one imaging modality has been given preference over the others and the omission of any agent(s) or the introduction of any errors in the list is purely unintentional. The MIP & CA List is subject to the same copyright and disclaimers as the rest of the MICAD content. The database includes, but is not limited to, agents developed for positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), ultrasound (US), computed tomography (CT), optical imaging, planar radiography, and planar gamma imaging. The information on each agent is summarized in a book chapter format containing several sections such as Background, Synthesis, in vitro studies, Animal Studies (with sub-sections: rodents, other non-human primate animals, and human primates), Human Studies, and References. In addition, the references are linked to PubMed for retrieval of the publication abstract. Also, each chapter contains links to resources at the National Center for Biotechnology Information (NCBI) and other relevant databases regarding the target of the imaging probe or contrast agent.

Proper citation: Molecular Imaging and Contrast Agent Database (RRID:SCR_006712) Copy   

•   Source: SciCrunch Registry
  

http://pdsp.med.unc.edu/snidd/

A database of imaging probes useful for preclinical and clinical studies. The National Institute of Mental Health (NIMH) and the Society for Non-Invasive Imaging in Drug Development (SNIDD) are in the process of creating a centralized, searchable PET, SPECT, and MRI tracer database as a resource for the scientific community. The goal of this effort is to promote the use of imaging probes in preclinical and clinical research and in drug discovery to accelerate the identification and validation of novel targets for therapeutic intervention in human diseases, especially those with central nervous system components. NIMH will maintain the tracer database as part of the Psychoactive Drug Screening Program (PDSP). The database will contain records for each radiotracer with relevant information such as target, research uses, pharmacology, pharmacokinetics, synthesis protocols, toxicology and safety data, dosimetry, other clinical data, IND info, permission to cross-reference pharmacology, toxicology, or safety data in a drug master file (if an IND exists), contact information, patent, etc. with appropriate safeguards in place to protect the intellectual property of proprietary compounds.

Proper citation: NIMH/SNIDD Tracer Database Initiative (RRID:SCR_008105) Copy   

•   Source: SciCrunch Registry
  

http://www.ohsu.edu/xd/research/research-cores/small-animal-research-imaging-core/

Provides in vivo imaging technology to evaluate anatomy, tissue function, cellular and molecular phenotype, blood/fluid flow, metabolism and to assess pharmacokinetics and stem cell function in small animal models.Offers spatial resolution, temporal resolution, tissue differentiation, sensitivity for contrast agent, and performance of contrast agents. Services include MicroPET/SPECT/CT imaging,Ultra-high frequency small animal ultrasound imaging,Biophotonics imaging.

Proper citation: Oregon Health and Science University Small Animal Research Imaging Core Facility (RRID:SCR_022742) Copy   

•   Source: SciCrunch Registry
  

https://www.moffitt.org/research-science/shared-resources/small-animal-imaging-lab/

Core provides advanced and affordable multi-modality imaging services including consultation, imaging and image analysis for both basic and translational research. Offers instrumentation including 7T MRI, multimodal PET/SPECT/CT, ultrasound and optical modalities. Used to evaluate tumor development, progression, metastasis and therapy response in rodent models of cancer including development of imaging biomarkers, contrast agents and tumor targeting agents, evaluating tumor metabolism and microenvironment, and high-resolution anatomical imaging of human specimens.

Proper citation: Moffitt Cancer Center Small Animal Imaging Laboratory Core Facility (RRID:SCR_012401) Copy   

•   Source: SciCrunch Registry
  

https://microctcore.med.umich.edu/home

Core provides services for acquiring three-dimensional imaging and quantitative analysis of biological and engineered structures/materials. The core is capable of imaging mineralized tissues (e.g., bone, teeth) and soft tissues (e.g., tendons, ligaments, cartilage, blood vessels, muscle) with the aid of radiographic contrast agents. This core is managed and operated by members of the Orthopaedic Research Laboratories.

Proper citation: University of Michigan Micro and Nano Computed Tomography Advanced Imaging Core Facility (RRID:SCR_026772) Copy   

•   Source: SciCrunch Registry
  

https://www.pennmedicine.org/departments-and-centers/department-of-radiology/radiology-research/labs-and-centers/quantitative/ultrasound-research-laboratory

Develops new ultrasound technologies and clinical applications, to bridge gap between technology and clinical applications, and to provide ultrasound imaging resources to other research. Consists of core group of scientists, sonographers and technicians with expertise in ultrasound technology and computer programming. This group works with clinicians in multiple specialties; including radiologists, cardiologists and surgeons. Core provides ultrasound scanner, sonographer and part-time radiologist on staff to conduct clinical and pre-clinical imaging.Helps with studies involving measurement of angiogenesis, vascularity, tissue elasticity, contrast agents, and effects of various physical and pharmaceutical agents on blood flow and tissue vascularity. Studies include research on cancer, cardiovascular disease and musculoskeletal disease.

Proper citation: University of Pennsylvania Perelman School of Medicine Ultrasound Research Laboratory Core Facility (RRID:SCR_022431) Copy   

•   Source: SciCrunch Registry
  

https://cores.research.asu.edu/preclinical-imaging/about

Core is dedicated to advancing biomedical discovery through modern and highly advanced imaging technologies. Provides access to high-resolution, non- and minimally invasive imaging tools that enable visualization of biological processes in vivo. Core offers imaging services including MR Solutions Multi-Field MRI systems (3T, 7T, and 9.4T) for detailed anatomical and functional imaging, the IVIS Lumina S5 platform for sensitive bioluminescence and fluorescence imaging, and the TriTom Photoacoustic Imager for high-contrast 3D photoacoustic visualization and multi-spectral imaging of molecular and vascular dynamics.Facility supports a wide range of preclinical applications. These include longitudinal animal studies, drug development, biomarker discovery, and validation of novel imaging agents.

Proper citation: Arizona State University Knowledge Enterprise Preclinical Imaging Core Facility (RRID:SCR_028601) Copy   

•   Source: SciCrunch Registry
  

http://www.scienceexchange.com/facilities/magnetic-resonance-laboratory-georgia-tech

The Nanomedicine Research Institute Magnetic Resonance Laboratory at Georgia Tech operates a Bruker Pharmascan 7T with a magnet bore of 160 mm. We have a large expertise in the use of MRI as a tool in Biomedical and Chemical Engineering. Previous research projects were concerned with: MRI of anatomical preparations; evaluation of tumor growth; bio-compatibility of implants; cardiac MRI; Diffusion Tensor Imaging; pharmacokinetics; fluid ingress and distribution in complex substrates; flow MRI; 1H, 19F and 13P in vivo spectroscopy and relaxometry; development of MRI contrast agents; solid-state MRI.

Proper citation: Georgia Tech Magnetic Resonance Laboratory (RRID:SCR_012326) Copy   

•   Source: SciCrunch Registry
  

http://www.scienceexchange.com/facilities/am-biotechnologies-llc

AM Biotechnologies develops DNA-based affinity agents called thioaptamers using unique chemistries and a proprietary bead-based selection process. Antibodies are currently the most widely-used affinity agents but they are produced in animals; are easily degraded; are expensive to produce; and suffer from batch-to-batch variability. In contrast, thioaptamers are chemically synthesized; they are stable in ambient environments with very long shelf life; and are rapidly produced in large quantities with easy quality control. We solve the problems associated with antibodies while delivering the same functionality. Thioaptamers can be substituted for antibodies in virtually any application. We can develop thioaptamer affinity agents for your targets using our bead-based development service. AM also offers DNA thiophosphoramidite reagents via a strategic partnership with Glen Research Corporation and the RNA thiophosphoramidites are near market introduction. These unique reagents are used to synthesize thioaptamers and are also highly useful for providing in vivo stability and increased potency in RNAi applications. The company was founded in 2006 and is primarily owned by two corporations. It has been awarded numerous SBIR grants and has also benefited from over $10M of prior university research into its technologies. Importantly, all of our technologies have freedom to operate.

Proper citation: AM Biotechnologies (RRID:SCR_012568) Copy   

•   Source: SciCrunch Registry
  

https://www.bruker.com/zh/products-and-solutions/preclinical-imaging/micro-ct/skyscan-1278.html

Scanner for in-vivo, low radiation imaging. Offers new micro-CT spatial beam shaper, which reduces absorbed radiation dose by up to five times while maintaining high quality image output. High throughput, high speed, microCT for scanning small laboratory animals including mice and rats. Has highly sensitive flat-panel detector that is able to deliver images of mouse heart and lung activities without using contrast agent, reducing animal stress and cost of study. Full-body animal scan can take 8 seconds or less, thus reducing overall run times and increasing the speed of data collection. Results can be directly sent to mobile devices for volume rendering and manipulations using software supplied.

Proper citation: Bruker: Skyscan 1278 Micro-CT Scanner (RRID:SCR_026204) Copy   

•   Source: SciCrunch Registry
  

http://nimh-repository.rti.org/

A program that synthesizes, purifies, and distributes otherwise unavailable essential compounds to stimulate basic and clinical research in psychopharmacology relevant to mental health in areas such as the molecular pharmacology and signaling of CNS receptors, longitudinal studies to evaluate the molecular, biochemical, and behavioral actions of psychoactive compounds, and functional brain imaging in both primates and humans. WHAT IS AVAILABLE: * Ligands for CNS receptors, radiolabeled compounds for autoradiography and neuroimaging, biochemical markers, drug analogs and metabolites, and reference standards * Synthesis (including GMP) of promising compounds for mental health research, including preclinical toxicology and safety studies, especially compounds for PET neuroimaging * A listing of currently available NIMH CSDSP compounds is available online at www.nimh-repository.rti.org. RTI International scientists can provide investigators with technical assistance and additional information about the compounds on request. Data sheets containing purity, storage, and handling information are supplied with all NIMH CSDSP compounds. WHO IS ELIGIBLE: Investigators involved in basic or clinical research relevant to mental health are eligible to submit requests. To learn more about current NIMH research areas, please visit the NIMH website at www.nimh.nih.gov. NIMH CSDSP compounds are free to qualified academic investigators, but payment may be required from nonacademic requestors. Investigators interested in obtaining radiolabeled compounds but uncertain about what type of label or specific activity would work best for them may obtain help by communicating with the technical contacts listed on the website.

Proper citation: NIMH Chemical Synthesis and Drug Supply Program (RRID:SCR_004921) Copy   

•   Source: SciCrunch Registry
  

http://www.mallinckrodt.com/

An independent global pharmaceutical company that produces specialty pharmaceutical products including generic drugs and imaging agents. They manufacture and distribute products used in diagnostic procedures and in the treatment of pain and related conditions. This includes the development, manufacture and distribution of specialty pharmaceuticals, active pharmaceutical ingredients, contrast products and radiopharmaceuticals. They are the largest U.S. supplier, by prescription, of opioid pain medications and the largest U.S. supplier of the medical isotope technetium-99m. The company is among the top 10 generic pharmaceuticals manufacturers in the United States. The company is also the largest producer of bulk acetaminophen. Mallinckrodt also produces cocaine derived from the Coca-Cola coca leaves, extracted by the Stepan Company. (Adapted from Wikipedia, 10/2014)

Proper citation: Mallinckrodt Pharmaceuticals (RRID:SCR_003986) Copy   

•   Source: SciCrunch Registry
  

http://purl.bioontology.org/ontology/OntoVIP

Ontology that describes the content of the models used in medical image simulation developed in the context of the Virtual Imaging Platform project (VIP), a french project aiming at sharing medical image simulation resources. This ontology can be used to annotate such models in order to highlight the different entities that are present in the 3D scene to be imaged, i.e. anatomical structures, pathological structures, foreign bodies, contrast agents etc. The model allows also to associate to these entities information about their physical qualities, which are used in the medical image simulation process (to mimick physical phenomena involved in CT, MR, US and PET imaging). This ontology partly relies on the OntoNeuroLOG ontology (ONL-DP ONL-MR-DA), as well as PATO, RadLex, FMA and ChEBI.

Proper citation: Medical image simulation (RRID:SCR_010355) Copy   

•   Source: SciCrunch Registry
  

http://www.utsouthwestern.edu/education/medical-school/departments/airc/southwestern-nmr-center/index.html

Biomedical technology research center that develops and applies new methods for analysis of metabolic networks in intact tissues, animals and human patients. The importance of understanding abnormal metabolism in common diseases such as cancer, diabetes and heart disease has long been appreciated. Because of constraints in technology, however, much of this research has been conducted in isolated systems where clinical relevance may be uncertain. Progress in magnetic resonance technology provides a foundation for major advances towards new ways of imaging metabolism in patients. These new techniques offer the advantage of imaging biochemical pathways without radiation. The focus of this Resource is to bring these technologies to a level where clinical research is feasible through the development of new MR contrast agents, NMR spectroscopy at high fields, and imaging of hyperpolarized 13C.

Proper citation: Southwestern NMR Center for In Vivo Metabolism (RRID:SCR_001429) Copy   

•   Source: SciCrunch Registry
  

http://em.emory.edu/protect/index.cfm

Recently, our team completed an NINDS-funded, Phase IIa double-blinded, placebo-controlled pilot clinical trial that examined the pharmacokinetics, safety, and activity of progesterone, a steroid found to have powerful neuroprotective effects in multiple animal models of brain injury. Our pilot study demonstrated a 50% reduction in death among severe TBI patients and less disability among moderate TBI patients treated with progesterone. Based on these promising results and supportive preclinical data, we are conducting a large, phase III clinical trial (ProTECT III) to definitively assess the safety and efficacy of this treatment for adults with moderate to severe acute TBI. The study is slated to begin August 2008. WHY Progesterone: Although progresterone is widely considered a sex steroid, it is also a potent neurosteroid. Progesterone is naturally synthesized in the CNS. A large and growing body of animal studies indicate that early administration of progesterone after TBI reduces cerebral edema, neuronal loss, and behavioral deficits in laboratory animals. Certain properties of progesterone make it an ideal therapeutic candidate. First, in contrast to most drugs tested to date, progesterone rapidly enters the brain and reaches equilibrium with the plasma within an hour of administration. Second, unlike other experimental agents, progesterone has a long history of safe use in humans. Finally, the findings of our pilot clinical trial (presented in the Preliminary Data Section, below) indicate that progesterone has consistent and predictable pharmacokinetic properties, is unlikely to produce harm, and may be efficacious for treating acute TBI in humans.

Proper citation: ProTECT (RRID:SCR_004531) Copy   

•   Source: SciCrunch Registry
  

http://icmic.rad.jhmi.edu/

The vision of the JHU ICMIC is to combine state-of-the-art imaging capabilities with powerful molecular biology techniques to define strategies with intent to cure. It has drawn upon its human resources at JHU to create a center consisting of a multidisciplinary group of premier individuals with diverse skills focused on translating molecular capabilities into imaging possibilities with the single purpose of understanding and curing cancer. Nearly all of the investigators participating in this ICMIC have interactive collaborative projects with one or more of the other investigators. The synergism generated by the collective skills of this unique group of individuals will lead to significant advances in the understanding of cancer and its treatment. The JHU ICMIC structure consists of four interactive and closely related research components focused on hypoxia, HIF-1, and exploiting the hypoxia response element to target cancer cells through choline kinase inhibition. These research components are anchored by the participation of world renowned expertise in HIF-1. The research components utilize MR, PET and Optical Imaging technology to understand cancer vascularization, invasion and metastasis, to achieve effective cancer therapy. The center has selected developmental projects which are highly relevant to the goals of the ICMIC and interactive with the research components. Five resources devoted to adminstration, molecular biology, imaging, probes, and translational application provide the infrastructure to support the research activities of the ICMIC. Research Components in the JHU ICMIC: - Combining Anti-angiogenic therapy with siRNA targeting of choline kinase. - Imaging the Role of HIF-1 in Breast Cancer Progression - Imaging and Targeting Hypoxia in Solid Tumors - Molecular and Functional Imaging of the HER-2/neu Receptor The following are developmental projects currently taking place in ICMIC 1. Receptor imaging using nonparamagnetic MRI contrast agents (2003) 2. New imaging agents for prostate cancer (2003) 3. Non-invasive monitoring of therapeutic effect of siRNA-mediated radiation sensitization in human prostate cancer xenografts (2003) 4. Imaging of the endothelin receptor in cancer (2003) 5. Imaging studies of c-myc regulation of tumor metabolism (2003) 6. Imaging studies of anti-tumorigenic effects of anti-oxidants in vivo (2005) 7. Molecular Imaging with Magnetic Resonance Microsystems (2005) 8. Endogenous angiogenesis inhibitors (2005) 9. MR imaging and spectroscopy in detection and localization of prostate cancer: a prospective trial in patients undergoing cystoprostatectomy and radical prostatectomy. (2005) 10. A versatile visualization system for the analysis of multi-modality and multidimensional cancer imaging (2007) 11. Non-invasive imaging of CXCR4 expression in breast cancer (2007)

Proper citation: John Hopkins University, In-Vivo Cellular Molecular Imaging Center (RRID:SCR_013198) Copy   

•   Source: SciCrunch Registry
  

http://www.ncbi.nlm.nih.gov/pubmed/

Public bibliographic database that provides access to citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites. PubMed citations and abstracts include fields of biomedicine and health, covering portions of life sciences, behavioral sciences, chemical sciences, and bioengineering. Provides access to additional relevant web sites and links to other NCBI molecular biology resources. Publishers of journals can submit their citations to NCBI and then provide access to full-text of articles at journal web sites using LinkOut.

Proper citation: PubMed (RRID:SCR_004846) Copy   

•   Source: SciCrunch Registry
  

http://www.ncbi.nlm.nih.gov

A portal to biomedical and genomic information. NCBI creates public databases, conducts research in computational biology, develops software tools for analyzing genome data, and disseminates biomedical information for the better understanding of molecular processes affecting human health and disease.

Proper citation: NCBI (RRID:SCR_006472) Copy   

•   Source: SciCrunch Registry
  

http://www.nlm.nih.gov/bsd/pmresources.html

A premier bibliographic database that contains over 18 million references to journal articles in life sciences with a concentration on biomedicine. A distinctive feature is that the records are indexed with NLM Medical Subject Headings (MeSH). PubMed provides free access to MEDLINE and links to full text articles when possible. The great majority of journals are selected for MEDLINE based on the recommendation of the Literature Selection Technical Review Committee (LSTRC), an NIH-chartered advisory committee of external experts analogous to the committees that review NIH grant applications. Some additional journals and newsletters are selected based on NLM-initiated reviews, e.g., history of medicine, health services research, AIDS, toxicology and environmental health, molecular biology, and complementary medicine, that are special priorities for NLM or other NIH components. These reviews generally also involve consultation with an array of NIH and outside experts or, in some cases, external organizations with which NLM has special collaborative arrangements. MEDLINE is the primary component of PubMed, part of the Entrez series of databases provided by the NLM National Center for Biotechnology Information (NCBI). MEDLINE may also be searched via the NLM Gateway. Time coverage: generally 1946 to the present, with some older material. Source: Currently, citations from approximately 5,516 worldwide journals in 39 languages; 60 languages for older journals. Citations for MEDLINE are created by the NLM, international partners, and collaborating organizations.

Proper citation: MEDLINE (RRID:SCR_002185) Copy   

•   Source: SciCrunch Registry